{"description":"Documents matching 'nicotinamide adenine'","count":13,"total_pages":1,"results":[{"title":"Nicotinamide; Exemption From the Requirement of a Tolerance","type":"Rule","abstract":"This regulation establishes an exemption from the requirement of a tolerance for residues of nicotinamide (CAS Reg. No. 98-92-0) when used as an inert ingredient (corrosion inhibitor) on growing crops only and limited to 5.0% in a pesticide formulation. Dow AgroSciences LLC submitted a petition to EPA under the Federal Food, Drug, and Cosmetic Act (FFDCA), requesting an amendment to an existing requirement of a tolerance. This regulation eliminates the need to establish a maximum permissible level for residues of nicotinamide.","document_number":"2019-20528","html_url":"https://www.federalregister.gov/documents/2019/10/03/2019-20528/nicotinamide-exemption-from-the-requirement-of-a-tolerance","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2019-10-03/pdf/2019-20528.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2019-20528.pdf?1570020314","publication_date":"2019-10-03","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"humans is well understood. <span class=\"match\">Nicotinamide</span> is necessary for lipid metabolism, tissue respiration and glycogenolysis. It is readily absorbed in the gastrointestinal (g.i.) tract. \n In vivo, \n <span class=\"match\">nicotinamide</span> is formed from the conversion of nicotinic acid (niacin), while some dietary <span class=\"match\">nicotinamide</span> is oxidized to nicotinic acid and then to <span class=\"match\">nicotinamide</span>. <span class=\"match\">Nicotinamide</span> is incorporated into two coenzymes: <span class=\"match\">Nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide (NAD) and <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide phosphate (NADP) which act as hydrogen-carrier molecules in glycogenolysis, tissue"},{"title":"Amendments to the List of Bulk Drug Substances That Can Be Used to Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act","type":"Proposed Rule","abstract":"The Food and Drug Administration (FDA or Agency) has issued a regulation creating a list of bulk drug substances (active pharmaceutical ingredients) that can be used to compound drug products in accordance with certain compounding provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act), although they are neither the subject of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph nor components of FDA-approved drugs. This proposed rule would amend that list by placing five additional bulk drug substances on the list. This proposed rule also identifies 26 bulk drug substances that FDA has considered and proposes not to include on the list. Additional substances nominated by the public for inclusion on this list are currently under consideration and will be the subject of a future rulemaking.","document_number":"2019-18951","html_url":"https://www.federalregister.gov/documents/2019/09/05/2019-18951/amendments-to-the-list-of-bulk-drug-substances-that-can-be-used-to-compound-drug-products-in","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2019-09-05/pdf/2019-18951.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2019-18951.pdf?1567601117","publication_date":"2019-09-05","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":" \n boswellia serrata \n extract (BWSE), cesium chloride, chondroitin sulfate, chrysin, curcumin, D-ribose, deoxy-D-glucose, diindolylmethane, domperidone, epigallocatechin gallate (EGCG), germanium sesquioxide, glycyrrhizin, kojic acid, nettle, <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide (NAD), <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide disodium reduced (NADH), rubidium chloride, sodium dichloroacetate, vanadyl sulfate, and vasoactive intestinal peptide (VIP).\n \n C. Legal Authority \n Section 503A of the FD&amp;C Act, in conjunction with our general rulemaking authority"},{"title":"Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments","type":"Notice","abstract":"The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pharmacy Compounding Advisory Committee (PCAC). The general function of the committee is to provide advice on scientific, technical, and medical issues concerning drug compounding under the Federal Food, Drug, and Cosmetic Act (the FD&C Act), and, as required, any other product for which FDA has regulatory responsibility, and to make appropriate recommendations to the Agency. The meeting will be open to the public.","document_number":"2017-07667","html_url":"https://www.federalregister.gov/documents/2017/04/17/2017-07667/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-04-17/pdf/2017-07667.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-07667.pdf?1492173951","publication_date":"2017-04-17","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"nominated bulk drug substances: <span class=\"match\">Nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide, <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide disodium reduced, nettle (\n Urtica dioica \n ) whole plant, ubiquinol, vanadyl sulfate, and artemisinin. The chart below describes which use(s) FDA reviewed for each of the six bulk drug substances being discussed at this \n \n advisory committee meeting. The nominators of these substances will be invited to make a short presentation supporting the nomination.\n \n \n   \n \n Drug \n Use(s) reviewed \n \n \n <span class=\"match\">Nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide \n Reducing fatigue"},{"title":"Expedited Approval of Alternative Test Procedures for the Analysis of Contaminants Under the Safe Drinking Water Act; Analysis and Sampling Procedures","type":"Rule","abstract":"This action announces the U.S. Environmental Protection Agency's (EPA's) approval of alternative testing methods for use in measuring the levels of contaminants in drinking water and determining compliance with national primary drinking water regulations. The Safe Drinking Water Act authorizes EPA to approve the use of alternative testing methods through publication in the Federal Register. EPA is using this streamlined authority to make 16 additional methods available for analyzing drinking water samples. This expedited approach provides public water systems, laboratories, and primacy agencies with more timely access to new measurement techniques and greater flexibility in the selection of analytical methods, thereby reducing monitoring costs while maintaining public health protection.","document_number":"2016-16516","html_url":"https://www.federalregister.gov/documents/2016/07/19/2016-16516/expedited-approval-of-alternative-test-procedures-for-the-analysis-of-contaminants-under-the-safe","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-07-19/pdf/2016-16516.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-16516.pdf?1468845934","publication_date":"2016-07-19","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"Drinking Water (NECi 2016a). The NECi nitrate reductase method is used for the determination of nitrate plus nitrite (as nitrogen) in drinking water. In this method, a eukaryotic nitrate reductase is used to catalyze the conversion of nitrate to nitrite in the presence of <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide as a reductant in a buffer with a near neutral pH. The combined nitrite (both the original and reduced nitrate) is reacted with sulfanilamide and N-(1-napthyl) ethylenediamine dihydrochloride to produce a chromophore. The combined nitrite concentration"},{"title":"Government-Owned Inventions; Availability for Licensing","type":"Notice","abstract":"The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.","document_number":"2012-10637","html_url":"https://www.federalregister.gov/documents/2012/05/03/2012-10637/government-owned-inventions-availability-for-licensing","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10637.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2012-10637.pdf?1335963095","publication_date":"2012-05-03","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"Agreement will be required to receive copies of the patent applications. \n Mouse Monoclonal Antibody Targeting Human NOX1, a Target for Cancer and Inflammation \n \n Description of Technology: \n Available for licensing is a mouse monoclonal antibodies targeting human <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide phosphate-oxidase (NAPH) oxidase 1 (NOX1) enzyme. NOX mediates the homeostasis of reactive oxygen species, which play a critical regulatory role in cancer cell signal transduction and tumor cell differentiation. NOX1-generated hydrogen peroxide can trigger"},{"title":"Government-Owned Inventions; Availability for Licensing: Mouse Models","type":"Notice","abstract":"The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.","document_number":"2012-9775","html_url":"https://www.federalregister.gov/documents/2012/04/24/2012-9775/government-owned-inventions-availability-for-licensing-mouse-models","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2012-04-24/pdf/2012-9775.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2012-09775.pdf?1335185721","publication_date":"2012-04-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"(Sirt1\n tm1.1Cxd \n ) Mouse Model for Oncology and Metabolism Studies\n \n \n Description of Mouse: \n Sirt1 knockout: Sirt1, a protein deacetylase, is a tumor suppressor that promotes genome stability and regulates proteins involved in energy metabolism.\n \n Yeast Sir2, a <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide (NAD)-dependent protein deacetylase, has been implicated in chromatin silencing, longevity and genome stability. Mammals contain a family of related deacetylases, the sirtuins, of which 7 have been identified. Sirt1 is the closest mammalian orthologue"},{"title":"Government-Owned Inventions; Availability for Licensing","type":"Notice","abstract":"The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of Federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.","document_number":"2010-30278","html_url":"https://www.federalregister.gov/documents/2010/12/02/2010-30278/government-owned-inventions-availability-for-licensing","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2010-12-02/pdf/2010-30278.pdf","public_inspection_pdf_url":null,"publication_date":"2010-12-02","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"Isocitrate Dehydrogenase 1 (IDH1) R132 Mutation Human Melanoma Metastasis Cell Line \n \n Description of Technology: \n Isocitrate dehydrogenase 1 (IDH1) plays an important role in glucose metabolism in the cytoplasm, converting isocitrate to α-ketoglutarate while reducing <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide phosphate (NADP+ to NADPH). However, when IDH1 harbors a R132 mutation it results in the accumulation of 2-hydroxyglutarate and has a corresponding association with cancer. This mutation in IDH1 has previously been identified in approximately 80% of progressive"},{"title":"Government-Owned Inventions; Availability for Licensing","type":"Notice","abstract":"The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of Federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.","document_number":"2010-5764","html_url":"https://www.federalregister.gov/documents/2010/03/17/2010-5764/government-owned-inventions-availability-for-licensing","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2010-03-17/pdf/2010-5764.pdf","public_inspection_pdf_url":null,"publication_date":"2010-03-17","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"therapeutic agents. \n The inventors also hypothesize that it would be possible to develop a treatment that increases levels of an ADP-ribosylated therapeutic protein, such as HNP-1, in the lung via inhalation administration of the therapeutic protein in conjunction with <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide (NAD), which is required for ADP-ribosylation. This could represent a unique therapeutic strategy for treating pulmonary disease. \n \n Applications: \n Development of defensin-based therapeutics that enhance the immune response in pulmonary disease patients"},{"title":"National Ambient Air Quality Standards for Ozone","type":"Proposed Rule","abstract":"Based on its reconsideration of the primary and secondary national ambient air quality standards (NAAQS) for ozone (O<INF>3</INF>) set in March 2008, EPA proposes to set different primary and secondary standards than those set in 2008 to provide requisite protection of public health and welfare, respectively. With regard to the primary standard for O<INF>3</INF>, EPA proposes that the level of the 8-hour primary standard, which was set at 0.075 ppm in the 2008 final rule, should instead be set at a lower level within the range of 0.060 to 0.070 parts per million (ppm), to provide increased protection for children and other \"at risk\" populations against an array of O<INF>3</INF>-related adverse health effects that range from decreased lung function and increased respiratory symptoms to serious indicators of respiratory morbidity including emergency department visits and hospital admissions for respiratory causes, and possibly cardiovascular-related morbidity as well as total non-accidental and cardiopulmonary mortality. With regard to the secondary standard for O<INF>3</INF>, EPA proposes that the secondary O<INF>3</INF> standard, which was set identical to the revised primary standard in the 2008 final rule, should instead be a new cumulative, seasonal standard expressed as an annual index of the sum of weighted hourly concentrations, cumulated over 12 hours per day (8 am to 8 pm) during the consecutive 3-month period within the O<INF>3</INF> season with the maximum index value, set at a level within the range of 7 to 15 ppm- hours, to provide increased protection against O<INF>3</INF>-related adverse impacts on vegetation and forested ecosystems.","document_number":"2010-340","html_url":"https://www.federalregister.gov/documents/2010/01/19/2010-340/national-ambient-air-quality-standards-for-ozone","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2010-01-19/pdf/2010-340.pdf","public_inspection_pdf_url":null,"publication_date":"2010-01-19","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"e and net photosynthesis in ozone-treated potato foliage. PlantPhysiol. 91: 427-432. \n David, G. L.; Romieu, I.; Sienra-Monge, J. J.; Collins, W. J.; Ramirez-Aguilar, M.; Del Rio-Navarro, B. E.; Reyes-Ruiz, N. I.; Morris, R. W.; Marzec, J. M.; London, S. J. (2003) <span class=\"match\">Nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide (phosphate) reduced:quinone oxidoreductase and glutathione s-transferase m1 polymorphism and childhood asthma. Am. J. Respir. Crit. Care Med. 168: 1199-1204. \n Davison, A. W.; Reiling, K. (1995) A rapid change in ozone resistance of Plantago major after"},{"title":"National Ambient Air Quality Standards for Ozone","type":"Proposed Rule","abstract":"Based on its review of the air quality criteria for ozone (O<INF>3</INF>) and related photochemical oxidants and national ambient air quality standards (NAAQS) for O<INF>3</INF>, EPA proposes to make revisions to the primary and secondary NAAQS for O<INF>3</INF> to provide requisite protection of public health and welfare, respectively, and to make corresponding revisions in data handling conventions for O<INF>3</INF>. With regard to the primary standard for O<INF>3</INF>, EPA proposes to revise the level of the 8-hour standard to a level within the range of 0.070 to 0.075 parts per million (ppm), to provide increased protection for children and other \"at risk\" populations against an array of O<INF>3</INF>-related adverse health effects that range from decreased lung function and increased respiratory symptoms to serious indicators of respiratory morbidity including emergency department visits and hospital admissions for respiratory causes, and possibly cardiovascular-related morbidity as well as total nonaccidental and cardiopulmonary mortality. The EPA also proposes to specify the level of the primary standard to the nearest thousandth ppm. The EPA solicits comment on alternative levels down to 0.060 ppm and up to and including retaining the current 8-hour standard of 0.08 ppm (effectively 0.084 ppm using current data rounding conventions). With regard to the secondary standard for O<INF>3</INF>, EPA proposes to revise the current 8-hour standard with one of two options to provide increased protection against O<INF>3</INF>-related adverse impacts on vegetation and forested ecosystems. One option is to replace the current standard with a cumulative, seasonal standard expressed as an index of the annual sum of weighted hourly concentrations, cumulated over 12 hours per day (8 a.m. to 8:00 p.m.) during the consecutive 3- month period within the O<INF>3</INF> season with the maximum index value, set at a level within the range of 7 to 21 ppm-hours. The other option is to make the secondary standard identical to the proposed primary 8-hour standard. The EPA solicits comment on specifying a cumulative, seasonal standard in terms of a 3-year average of the annual sums of weighted hourly concentrations; on the range of alternative 8-hour standard levels for which comment is being solicited for the primary standard, including retaining the current secondary standard, which is identical to the current primary standard; and on an alternative approach to setting a cumulative, seasonal secondary standard(s).","document_number":"E7-12416","html_url":"https://www.federalregister.gov/documents/2007/07/11/E7-12416/national-ambient-air-quality-standards-for-ozone","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2007-07-11/pdf/E7-12416.pdf","public_inspection_pdf_url":null,"publication_date":"2007-07-11","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"se and net photosynthesis in ozone-treated potato foliage. PlantPhysiol. 91: 427-432. \n David, G. L.; Romieu, I.; Sienra-Monge, J. J.; Collins, W. J.; Ramirez-Aguilar, M.; Del Rio-Navarro, B. E.;Reyes-Ruiz, N. I.; Morris, R. W.; Marzec, J. M.; London, S. J. (2003) <span class=\"match\">Nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide (phosphate) reduced:quinone oxidoreductase and glutathione s-transferase m1 polymorphism and childhood asthma. Am. J. Respir. Crit. Care Med. 168: 1199-1204. \n Davison, A. W.; Reiling, K. (1995) A rapid change in ozone resistance of Plantago major after"},{"title":"Government-Owned Inventions; Availability for Licensing","type":"Notice","abstract":"The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.","document_number":"05-5875","html_url":"https://www.federalregister.gov/documents/2005/03/24/05-5875/government-owned-inventions-availability-for-licensing","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2005-03-24/pdf/05-5875.pdf","public_inspection_pdf_url":null,"publication_date":"2005-03-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"cholera toxin and diphtheria toxin catalyze the ADP-ribosylation of important cellular target proteins in their human hosts, thereby, as in the case of cholera toxin, irreversibly activating adenylyl cyclase. In this reaction, the toxin transfers the ADP-ribose moiety of <span class=\"match\">Nicotinamide</span> <span class=\"match\">Adenine</span> Dinucleotide (NAD) to an acceptor amino acid in a protein or peptide. ADP-ribosylation leads to a peptide/protein with altered biochemical or pharmacological properties. Mammalians proteins catalyze reactions similar to the bacterial toxins. The ADP-ribosylated proteins"},{"title":"Government-Owned Inventions; Availability for Licensing","type":"Notice","abstract":"The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.","document_number":"02-32350","html_url":"https://www.federalregister.gov/documents/2002/12/24/02-32350/government-owned-inventions-availability-for-licensing","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2002-12-24/pdf/02-32350.pdf","public_inspection_pdf_url":null,"publication_date":"2002-12-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":"toxin and diphtheria toxin catalyze the ADP-ribosylation of important cellular target proteins in their human hosts, thereby, as in the case of cholera toxin, irreversibly activating adenylate cyclase. In this reaction, the toxin transfers the ADP-ribose moiety of <span class=\"match\">Nicotinamide</span> <span class=\"match\">Adenine</span> Dinucleotide (NAD) to an acceptor amino acid in a protein or peptide. ADP-ribosylation leads to a peptide/protein with altered biochemical or pharmacological properties. Mammalians proteins catalyze reactions similar to the bacterial toxins. The ADP-ribosylated proteins"},{"title":"Methoxychlor; Proposed Revocation of Tolerances","type":"Proposed Rule","abstract":"This document proposes to revoke specific tolerances for residues of methoxychlor because (1) all registrations of pesticides containing methoxychlor are suspended or canceled, and (2) there are insufficient data to find the pesticide safe in accordance with section 4(b)(2)(A) of the Federal Food, Drug, and Cosmetic Act (FFDCA). The primary registrant of methoxychlor (Kincaid Enterprises, Inc.) has failed to submit the necessary data required to support continued registration under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) of pesticide products containing methoxychlor. As a result, all methoxychlor products are currently suspended. The regulatory actions proposed in this document contribute toward the Agency's tolerance reassessment requirements of the Federal Food, Drug, and Cosmetic Act (FFDCA) section 408(q), as amended by the Food Quality Protection Act (FQPA) of 1996. By law, EPA is required by August 2002 to reassess 66% of the tolerances in existence on August 2, 1996, or about 6,400 tolerances. The regulatory actions proposed in this document pertain to the proposed revocation of 79 tolerances and/or exemptions which would be counted among tolerance/exemption reassessments made toward the August 2002 review deadline.","document_number":"02-8155","html_url":"https://www.federalregister.gov/documents/2002/04/04/02-8155/methoxychlor-proposed-revocation-of-tolerances","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2002-04-04/pdf/02-8155.pdf","public_inspection_pdf_url":null,"publication_date":"2002-04-04","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"literature in connection with endocrine disruption. Kupfer and Bulger (Ref. 5) found that both methoxychlor and metabolites have estrogen-like activity with several metabolites having proestrogen activity. They used an \n in vitro \n system involving rat liver microsomes and <span class=\"match\">nicotinamide</span> <span class=\"match\">adenine</span> dinucleotide phosphate (NADPH) for a metabolizing system with estrogen receptors from immature rat uteri as a detection system.\n \n \n Gray et al. (Ref. 3) investigated the effects of methoxychlor on the pubertal development and reproductive function in the male and"}]}